NAMS
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$25.40
−1.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1M | 22.5M | 45.6M | 14.1M | 102.7M |
| Cost of Revenue | 559.0K | 59.0K | — | — | — |
| Gross Profit | 6.6M | 22.4M | 45.6M | 14.1M | 102.7M |
| Operating Expenses | |||||
| R&D Expense | 148.7M | 141.8M | 151.4M | 159.4M | 86.7M |
| SG&A Expense | 102.2M | 106.3M | 70.4M | 37.6M | 19.5M |
| General & Admin Expense | 102.2M | 106.3M | 70.4M | 37.6M | 19.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 251.0M | 248.1M | 221.9M | 197.1M | 106.3M |
| Cost and Expenses | 251.5M | 248.2M | 221.9M | 197.1M | 106.3M |
| Operating Income (EBIT) | (244.4M) | (225.7M) | (176.3M) | (183.0M) | (3.6M) |
| Non-Operating | |||||
| Interest Income | 23.0M | 27.6M | 16.9M | 10.2M | — |
| Interest Expense | — | — | — | 6.8M | 287.0K |
| Net Interest Income | 23.0M | 27.6M | 16.9M | 3.4M | (287.0K) |
| Other Non-Op Income/Expense | (15.1M) | 21.9M | (65.3M) | 6.1M | (19.1M) |
| Non-Operating Income (excl Interest) | 10.7M | 16.9M | 65.3M | (6.1M) | 18.8M |
| EBT (Pre-Tax Income) | (259.5M) | (203.8M) | (241.6M) | (176.9M) | (22.6M) |
| Income Tax Expense | — | — | (1.0K) | 27.0K | — |
| Bottom Line | |||||
| Net Income | (259.5M) | (203.8M) | (241.6M) | (176.9M) | (22.6M) |
| Earnings from Cont. Ops | (259.5M) | (203.8M) | (241.6M) | (176.9M) | (22.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (259.5M) | (203.8M) | (241.6M) | (176.9M) | (22.6M) |
| Per Share | |||||
| Basic EPS | ($2.18) | ($1.75) | ($2.56) | ($2.15) | ($1.19) |
| Diluted EPS | ($2.18) | ($1.75) | ($2.56) | ($2.15) | ($1.19) |
| Revenue Per Share | $0.06 | $0.20 | $0.48 | $0.17 | $5.41 |
| Shares | |||||
| Basic Shares Outstanding | 123.4M | 114.4M | 94.4M | 82.2M | 19.0M |
| Diluted Shares Outstanding | 123.4M | 114.4M | 94.4M | 82.2M | 19.0M |
| Profitability Metrics | |||||
| EBITDA | (254.9M) | (242.3M) | (241.5M) | (176.9M) | (22.3M) |
| D&A | 274.0K | 220.0K | 113.0K | 49.0K | 9.0K |
| EBIT | (255.2M) | (242.5M) | (241.6M) | (176.9M) | (22.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026